2023-506063-34-00招募中1 期
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 9
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
EU GSK Clinical Trails Call Center
Scientific
Glaxosmithkline Research & Development Limited
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with RRMM (DREAMM 8)jRCT2011210067GlaxoSmithKline K.K.20
进行中（未招募）
1 期
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisEUCTR2020-004001-32-GREuropean Myeloma Network – EM36
进行中（未招募）
1 期
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisrelapsed or refractory AL amyloidosisMedDRA version: 20.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004001-32-FREuropean Myeloma Network – EM36
进行中（未招募）
1 期
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisRelapsed or refractory AL amyloidosis.MedDRA version: 20.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004001-32-ITSTICHTING EUROPEAN MYELOMA NETWORK36
尚未招募
2 期
A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisNL-OMON54340Stichting European Myeloma Network (EMN)2